Philipp Haselmayer
Darmstadt, HE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Identifying lupus Patient Subsets Through Immune Cell Deconvolution of Gene Expression Data in Two Atacicept Phase II Studies.
Journal: ACR open rheumatology
Published: December 22, 2022
Discovery of M5049: A Novel Selective Toll-Like Receptor 7/8 Inhibitor for Treatment of Autoimmunity.
Journal: The Journal of pharmacology and experimental therapeutics
Published: August 07, 2020
Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease.
Journal: Acta neuropathologica
Published: May 25, 2020
Identification of pharmacodynamic biomarker hypotheses through literature analysis with IBM Watson.
Journal: PloS one
Published: December 21, 2018
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: May 01, 2018
Diminished CXCR5 expression in peripheral blood of patients with Sjögren's syndrome may relate to both genotype and salivary gland homing.
Journal: Clinical and experimental immunology
Published: February 09, 2018
A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells.
Journal: European journal of immunology
Published: January 09, 2017
Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling.
Journal: Molecular pharmacology
Published: September 25, 2016
Showing 1-10 of 10
Last Updated: 09/26/2026